[A family of lysophospholipid receptors].

N. Fukushima

2000-09-01

Seikagaku. The Journal of Japanese Biochemical Society

Abstract:

What problem does this paper attempt to address?

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas

Xiaoping Zhang,Li Yang,Minyi Zhu,Xiaotian Zhao,Yao Xiao,Jiaohui Pang,Liuqing Zhu,Qiuxiang Ou,Hai-Wen Ni,Jingyan Xu

DOI: https://doi.org/10.1080/14796694.2024.2402209

Abstract:Aim: Advances in circulating tumor DNA (ctDNA) analysis for diffuse large B-cell lymphoma (DLBCL) have prompted the evaluation of its utility in other non-Hodgkin lymphomas (NHLs), leading to significant insights into its potential applications.Methods: We retrospectively studied paired plasma and tissue/bone marrow biopsies of 203 non-DLBCL NHLs [87 follicular lymphomas (FL), 64 mantle cell lymphomas (MCL), 30 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL) and 22 marginal zone lymphomas (MZL)]. Genomic profiling was performed using a targeted next generation sequencing panel (Hemasalus™). Longitudinal analyses were performed to explore plasma ctDNA utility in disease monitoring.Results: High plasma ctDNA detection rates were observed across NHL subtypes (FL: 88.5%, MCL: 90.6%, CLL/SLL: 100%, MZL: 68.2%), with high concordance of actionable mutations (FL: 87.4%, MCL: 93.8%, CLL/SLL: 93.3%, MZL: 81.8%) and multiple genetic aberrations exclusively identified in plasma. Particularly, IGH-BCL2 and IGH-CCND1 fusions were concordant between plasma and tumor biopsies in FLs (91.1%) and MCLs (91.3%), respectively. Longitudinal data demonstrated that ctDNA clearance correlated with complete response but ctDNA increases preceded radiological relapses.Conclusion: ctDNA exhibited high concordance with tumor biopsy in detecting genetic aberrations and demonstrated potential as a promising noninvasive approach to disease surveillance in non-DLBCL NHLs.
Choice of parenteral solutions for correcting metabolic acidosis.

M. D. Brown

1979-04-01

Abstract:
Circulating Tumor DNA: Clinical Roles in Diffuse Large B Cell Lymphoma

Fang-Tian Wu,Luo Lu,Wei Xu,Jian-Yong Li

DOI: https://doi.org/10.1007/s00277-018-3529-9

2018-01-01

Annals of Hematology

Abstract:Diffuse large B cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma (NHL), is a clinically and molecularly heterogeneous malignant lymphoproliferative disease. In the era of personalized medicine, genetic information is critical to early diagnosis, aiding risk stratification, directing therapeutic option, and monitoring disease relapse. However, lacking a circulating disease with most DLBCL cases hampers the acquisition of tumor genomic landscapes and disease dynamics. Circulating tumor DNA (ctDNA) is a novel noninvasive, real-time, and tumor-specific biomarker, reliably reflecting the comprehensive tumor genetic profiles, thus holds great promise in individualized medicine, including precise diagnosis and prognosis, response monitoring, and relapse detection of DLBCL. Here, we reviewed the recent advances of ctDNA in DLBCL and discussed its clinical values at different time points during the disease courses by comparing with the current routine methods in clinical practice. Collectively, we anticipated that ctDNA will ultimately be integrated into the management of DLBCL to facilitate precision medicine.
Thallium Lung-to-Heart Quantification: Three Methods of Evaluation

M. Harler,M. Mahoney,Bruce E. Bartlett,K. Patel,E. Turbiner

1986-12-01

Abstract:201 TI stress test images, has been found useful in diagnosing cardiac dysfunction. We evaluated three methods of quantification in terms of inter- and intraobserver variability and reproducibility. Fifty anterior 201 TI stress images were quantified by each of the following methods: Method A (sum region), which involved one region of interest (ROI) in the measurement of pul monary activity relative to that of the myocardium; Method B (count density), which required two ROis, the lung-to-heart ratio being dependent on count density; and Method C (maximum pixel), which used the gray scale of the computer to determine the most intense pixels in the lung field and myocardium. Statistical evaluation has shown that the three methods assess clinical data equally well. Method C was found to be most reproducible in terms of inter- and intraobserver variability (p = 0.0016 and 0.0083), followed by Meth ods A (p = 0.0026 and 0.0129) and B (p = 0.0038 and 0.0135). Al though nearly equivalent in terms of statistics, the three methods possess inherent differences and therefore should not be used inter changeably without conversion factors. Thallium-201 stress test imaging is useful in detecting coronary artery disease (CAD); as an adjunct to this examination, the lung-to-heart ratio provides additional knowledge of cardiac function. Previous studies suggest that increased pulmonary 201 Tl activity immediately after stress correlates with an increase in CAD (1). Furthermore, the lung to-heart ratio is held to be very specific for advanced CAD because increased activity appears to be a function of increased pulmonary capillary wedge pressures, reflecting development of transient, exercise-induced left ventricular failure (2). Given the clinical significance of the lung-to-heart ratio, we have evaluated three methods of quantification in terms of inter and intraobserver variability and reproducibility.
Prevention of early familial maladjustment by parent-staff group meetings: influence of familial background.

J. Allain,J. Bernard,D. Frommel,Y. Laurian,J. Proust

DOI: https://doi.org/10.1111/J.1600-0609.1984.TB02548.X

2009-04-24

Abstract:The possibility of preventing some major familial maladjustment following the diagnosis of severe haemophilia in the frame of free discussion group was explored. Five couples, 3 with a familial history of haemophilia and 2 without met 5 times over a 2 year period with 3 staff members for a full day. Transcripts of tape recorded sessions were analyzed. Parents with no familial history were apparently more affected but had a more dynamic approach towards hemophilia than the others. They benefited more from the program. Four of the five families were able to treat their child at home before 4 years of age. This new approach seems to help parents to adjust to this severe chronic disease and staff members to reconsider their interaction with parents.
A high frequency of structural chromosome abnormalities in a south central texas cytogenetics laboratory.

R. Young,K. Hansen,S. Shapiro,R. Jorgenson

DOI: https://doi.org/10.1002/AJMG.1320190217

1984-10-01

American Journal of Medical Genetics

Abstract:Abnormalities of chromosome number, such as the autosomal trisomies and sex chromosome aneuploidies, are considered to be sporadic events with low and constant recurrence risk across populations. On the other hand, abnormalities of chromosome structure can be generated by environmental agents and also transmitted in families and therefore may accumulate in certain populations. Evidence from several geographically diverse newborn infant screening studies and from clinical cytogenetics laboratories (including our own) supports the hypothesis that the frequency of structural abnormalities varies among populations, whereas the frequency of numerical abnormalities remains relatively constant among populations. The data from our laboratory, based on 1,201 patients over a 6-year period, suggest a two- to nearly fourfold higher frequency of structural defects over that of other populations (8.8% vs 4.2% and 2.5% of samples tested). Some of the problems associated with making comparisons among the published data sets are discussed, along with alternative explanations for the variability in the frequency of structural defects reported in different populations.
Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes

Jin Ju Kim,Hye Min Kim,Hongkyung Kim,Soo-Jeong Kim,Seung-Tae Lee,Jong Rak Choi,Saeam Shin,Doh Yu Hwang

DOI: https://doi.org/10.4143/crt.2023.667

Abstract:Purpose: We designed and evaluated the clinical performance of a plasma circulating tumor DNA (ctDNA) panel of 112 genes in various subtypes of lymphoma. Materials and methods: Targeted deep sequencing with an error-corrected algorithm was performed in ctDNA from plasma samples that were collected before treatment in 42 lymphoma patients. Blood buffy coat was utilized as a germline control. We evaluated the targeted gene panel using mutation detection concordance on the plasma samples with matched tissue samples analyzed the mutation profiles of the ctDNA. Results: Next-generation sequencing analysis using matched tissue samples was available for 18 of the 42 patients. At least one mutation was detected in the majority of matched tissue biopsy samples (88.9%) and plasma samples (83.3%). A considerable number of mutations (40.4%) that were detected in the tissue samples were also found in the matched plasma samples. Majority of patients (21/42) were diffuse large B cell lymphoma patients. The overall detection rate of ctDNA in patients was 85.7% (36/42). The frequently mutated genes included PIM1, TET2, BCL2, KMT2D, KLHL6, HIST1H1E, and IRF8. A cutoff concentration (4,506 pg/mL) of ctDNA provided 88.9% sensitivity and 82.1% specificity to predict ctDNA mutation detection. The ctDNA concentration correlated with elevated lactate dehydrogenase level and the disease stage. Conclusion: Our design panel can detect many actionable gene mutations, including those at low frequency. Therefore, liquid biopsy can be applied clinically in the evaluation of lymphoma patients, especially in aggressive lymphoma patients.
Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing

Yue Hou,Jie Zi,Shuo Liu,Qinyu Ge,Zheng Ge

DOI: https://doi.org/10.1002/mc.23476

Abstract:Liquid biopsy has been experimented with to identify the mutation of lymphoma based on next-generation sequencing (NGS). We applied NGS analysis to circulating tumor DNA (ctDNA) in 20 lymphoma patients. Then, we compared treatment outcomes, and clinical characteristics among these patients, then investigated mutational profiling. Two independent cohorts of 241 patients with mature B cell lymphoma in Mature B-cell malignancies data set (MBN) data set and 50 diffuse large B-cell lymphoma (DLBCL) patients in DLBCL data set, were used to examine the association between gene mutations and prognosis. We found ctDNA positive group had significantly more relapsed/PD (7/12, 58.3%) and less CR/PR patients (1/12, 8.3%) compared to negative group (0, 0%) (5/8, 62.5%) (p < 0.001). Somatic alterations were identified in 12 of 20 patients and the total 11 mutations were: Ataxia telangiectasia mutated (ATM), TP53, BCL2, BTG2, CD28, EP300, IDH2, IRF8, JAK3, NOTCH1, and NRAS. ATM (S2168L) was found in SLL and TLBL for the first time. BTG2 (c.292_293del), CD28 (P119T), IRF8 (E74D) and NOTCH1 (c.4348 G > A) were newly detected in DLBCL, angioimmunoblastic T-cell lymphoma, primary central nervous system lymphoma, and BCL for the first time respectively. We also disclosed an unreported mutation EP300 (c.1058_1059insC) in DLBCL. Our cases implied ctDNA detection consistent with the FISH of tissue samples to some extent, speculating new molecular subtypes of DLBCL, finding some potential drug-resistant mutations, and suggesting disease recurrence. Moreover, in MBN and DLBCL datasets, patients with TP53 mutation had a significantly shorter OS (all p < 0.05) in both circulating free DNA and tumor tissue. The mutations (no SNP) of NOTCH1 (all p < 0.05) significantly contributed to worse OS in the two cohorts.
Validation of Circulating Tumor DNA As an Alternative to Tumor Tissue Biopsy in Genotyping across Multiple Lymphoma Subtypes

Haisheng Liu,Yue Yuan,Lili Wu,Lanping Diao,Yuhuan Gao,Chengcheng Wang,Pingping Zou,Shanbo Cao,Jiayue Qin

DOI: https://doi.org/10.1182/blood-2023-180642

IF: 20.3

2023-11-28

Blood

Abstract:Introduction Genotyping plays an important role in the diagnosis, risk stratification and treatment response surveillance of lymphoma, a disease with considerable heterogeneity in clinical and pathological characteristics. To date, tumor tissue biopsy based genotyping is still considered as gold standard in lymphoma, but its application is hampered by the invasive nature and imperfect performance in capturing spatial and temporal tumor heterogeneity. Circulating tumor DNA (ctDNA), which is shed into peripheral blood by apoptotic or necrotic tumor cells, has shown the potential as a noninvasive alternative to tumor tissue DNA (tDNA) for molecular profiling. Many efforts have been made to investigate the feasibility of ctDNA based on next-generation sequencing (NGS) in lymphoma, but most of the studies were conducted in Caucasian population and limited to B-cell lymphoma patients. In the present study, we evaluated the performance of plasma-derived ctDNA against tDNA based genotyping across multiple lymphoma subtypes. Methods Between 4/2021 and 5/2023, a total of 110 patients were enrolled in this study. Matched tumor tissue biopsies and peripheral blood were collected at diagnosis. Both tDNA and ctDNA were extracted and subjected to a targeted capture NGS assay covering the entire coding region or recurrently mutated region of 196 genes. The mean coverage depth was 2431x and 2513x for tDNA and ctDNA, respectively. The limit of detection (LOD) was 1% and 0.5% for tDNA and ctDNA, respectively. Results The enrolled cohort comprised of 63 (57.3%) male and 47(42.7%) female patients, with a median age of 58 years old (range 1.25-89). Among the 110 patients, the most prevalent subtype is diffuse large B-cell lymphoma (DLBCL,n=45), following by angioimmunoblastic T-cell lymphoma (AITL, n=16), anaplastic large cell lymphoma (ALCL, n=13) , mantle cell lymphoma (MCL, n=10), follicular lymphoma (FL, n=9), primary mediastinal large B-cell lymphoma (PMBL, n=9), extranodal natural killer/T cell lymphoma (ENKTL, n=4), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS, n=4). For further analysis, DLBCL, MCL, FL and PMBL were categorized as B-cell lymphoma group (n=73), while AITL, ALCL, ENKTL and PTCL-NOS were categorized as T-cell lymphoma group (n=37). Mutations were detected in 109(99.10%)tDNA and 110(100%)ctDNA, respectively. A total of 1586 mutations involving 177 genes were detected in tDNA, and the median number of mutations per sample was 12 (range 0-62), with KMT2D (39.09%), KMT2C (30.90%), IGLL5 (30.00%), TET2 (25.45%) and TP53 (20.90%) being the top 5 mutated genes. For ctDNA, a total of 1750 mutations involving 178 genes were detected and the median number of mutations per sample was 14 (range 2-63), with KMT2D (37.27%), KMT2C (29.09%), IGLL5 (27.27%), TET2 (25.45%) and DNMT3A (27.27%) being the top 5 mutated genes. To determine the concordance of mutations detected in tDNA and ctDNA, sensitivity was calculated utilizing tDNA as gold standard. The overall sensitivity of ctDNA based genotyping was 85.39% (95%CI: 82.36%-88.41%), with B-cell lymphoma showing a slightly higher sensitivity than T-cell lymphoma (86.17%, 95%CI: 83.51%-88.83% vs. 83.84%, 95%CI: 76.30%-91.32%). In terms of subtypes, PTCL-NOS exhibited the highest sensitivity (89.58%, 95%CI: 56.43%-122.73%, while AITL exhibited the lowest sensitivity (78.53%, 95%CI: 64.09%-92.97%) (Figure 1A). In addition, the difference of mutational spectrum between B-cell lymphoma and T-cell lymphoma was precisely depicted by ctDNA based genotyping. We discovered mutations in TET2, RHOA, and PLCG1 were significantly present in T-cell lymphoma, while mutations in MYD88, CD79B, CARD11, CREBBP, MYC, PIM1, IGLL5, ATM, SOCS1 and HIST1HIE were significantly enriched in B-cell lymphoma (Figure 1B). Conclusion In the present study, recurrent mutations across a variety of lymphoma subtypes were identified by ctDNA based genotyping, which were in high concordance with tDNA based genotyping. These data demonstrated that ctDNA based genotyping is a reliable noninvasive alternative to tumor tissue biopsy for molecular profiling of lymphoma patients, especially for patients whose tissues are not accessible for genotyping.

hematology
Clinical use of circulating tumor DNA analysis in patients with lymphoma

Bettina Bisig,Karine Lefort,Sylvain Carras,Laurence de Leval

DOI: https://doi.org/10.1016/j.humpath.2024.105679

IF: 3.526

2024-11-04

Human Pathology

Abstract:The analysis of circulating tumor DNA (ctDNA) in liquid biopsy specimens has an established role for the detection of predictive molecular alterations and acquired resistance mutations in several tumors. The low-invasiveness of this approach allows for repeated sampling and dynamic monitoring of disease evolution. Originating from the entire body tumor bulk, plasma-derived ctDNA reflects intra- and interlesional genetic heterogeneity. In the management of lymphoma patients, ctDNA quantification at various timepoints of the patient's clinical history is emerging as a complementary tool that may improve risk stratification, assessment of treatment response and early relapse detection during follow-up, most prominently in patients with diffuse large B-cell lymphoma or classic Hodgkin lymphoma. While liquid biopsies have not yet entered standard-of-care treatment protocols in these settings, several trials have provided evidence that at least a subset of lymphoma patients may benefit from the introduction of liquid biopsies into daily clinical care. In parallel, continuous technological developments have enabled highly sensitive ctDNA assessment methods, which span from locus-specific techniques identifying single hotspot mutations, to sequencing panels and genome-wide approaches that explore broader genetic and epigenetic alterations. Here, we provide an overview of current methods and ongoing technical developments for ctDNA evaluation. We also summarize the most important data from a selection of clinical studies that have explored the clinical use of ctDNA in several lymphoma entities.

pathology
Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study

Vincent Camus,Mathieu Viennot,Emilie Lévêque,Pierre-Julien Viailly,David Tonnelet,Elena-Liana Veresezan,Fanny Drieux,Pascaline Etancelin,Sydney Dubois,Aspasia Stamatoullas,Hervé Tilly,Elodie Bohers,Fabrice Jardin

DOI: https://doi.org/10.1080/10428194.2021.2010060

2022-01-25

Abstract:Few data exist concerning circulating tumor DNA (ctDNA) relevance in primary mediastinal B-cell lymphoma (PMBL). To explore this topic, we applied a 9-gene next-generation sequencing pipeline to samples from forty-four PMBL patients (median age 36.5 years). The primary endpoint was a similarity between paired biopsy/plasma mutational profiles. We detected at least one variant in 32 plasma samples (80%). The similarity between the biopsy and ctDNA genetic profiles for the 30 patients with paired mutated biopsy/plasma samples was greater than or equal to 80% in 19 patients (63.3%). We then compared PMBL ctDNA features with those of a cohort of Hodgkin lymphoma patients (n = 60). The top three mutated genes were SOCS1, TNFAIP3, and B2M in both lymphoma types. PMBL displayed more alterations in TNFAIP3 (71.9% vs. 46.3%, p = 0.029) and GNA13 (46.9% vs. 17.1%, p = 0.013) than cHL. Our 9-gene set may delineate tumor genotypes using ctDNA samples from both lymphoma types.

oncology,hematology
Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma

Chong Wei,Wei Wang,Yan Zhang,Danqing Zhao,Wei Zhang,Daobin Zhou

DOI: https://doi.org/10.1111/bjh.18824

Abstract:In this prospective study, we aimed to evaluate the utility of circulating tumour DNA (ctDNA) in peripheral T-cell lymphomas (PTCLs). Plasma cell-free DNA (cfDNA) was obtained, and the mutational profile was assessed in 47 patients with newly diagnosed mature T- and NK-cell lymphoma. To validate the mutations detected in cfDNA, paired tumour tissue samples were available for 36 patients. Targeted next-generation sequencing was performed. A total of 279 somatic mutations involving 149 genes were identified in the 47 cfDNA samples. The overall sensitivity of plasma cfDNA in discovering biopsy-confirmed mutations was 73.9% with a specificity of 99.6%. When we considered only mutations with variant allele frequency >5% in the tumour biopsy, the sensitivity increased to 81.9%. Pretreatment ctDNA concentration and the number of mutations were highly correlated with tumour burden indicators including lactate dehydrogenase, Ann Arbor stage and International Prognostic Index score. Patients with high ctDNA level (>1.9 log ng/mL) had significantly lower overall response rates, inferior 1-year progression-free survival and overall survival rates than those with low level. Longitudinal analysis of ctDNA showed a strong agreement between ctDNA dynamics and the radiographic response. In conclusion, our study demonstrates that ctDNA may serve as a promising tool for mutational profiling, tumour burden assessment, outcome prediction and disease monitoring in PTCLs.
Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA

Sicong Zhang,Tingting Zhang,Hengqi Liu,Jing Zhao,Haifei Zhou,Xiaoxing Su,Xianming Liu,Lanfang Li,Lihua Qiu,Zhengzi Qian,Shiyong Zhou,Wenchen Gong,Bin Meng,Xiubao Ren,Jin He,Xianhuo Wang,Huilai Zhang

DOI: https://doi.org/10.1111/bjh.17894

Abstract:Diffuse large B-cell lymphoma (DLBCL) is a highly heterogenous malignancy, early identification of patients for relapse remains challenging. The potential to non-invasively monitor tumour evolutionary dynamics of DLBCL needs to be further established. In the present study, 17 tumour biopsy and 38 plasma samples from 38 patients with high-intermediate/high-risk DLBCL were evaluated at baseline. Longitudinal blood samples were also collected during therapy. Circulating tumour DNA (ctDNA) was analysed using targeted sequencing based on a gene panel via a recently developed methodology, circulating single-molecule amplification and re-sequencing technology (cSMART). We found that the most frequently mutated genes were tumour protein p53 (TP53; 42·1%), histone-lysine N-methyltransferase 2D (KMT2D; 28·9%), caspase recruitment domain family member 11 (CARD11; 21·1%), cAMP response element-binding protein binding protein (CREBBP; 15·8%), β2 -microglobulin (B2M; 15·8%), and tumour necrosis factor alpha-induced protein 3 (TNFAIP3; 15·8%). The mutation profiles between ctDNA and matched tumour tissue showed good concordance; however, more mutation sites were detected in ctDNA samples. Either TP53 or B2M mutations before treatment predicted poor prognosis. Analysis of dynamic blood samples confirmed the utility of ctDNA for the real-time assessment of treatment response and revealed that the increases in ctDNA levels and changes in KMT2D mutation status could be useful predictors of disease progression. Our present results suggest that ctDNA is a promising method for the detection of mutation spectrum and serves as a biomarker for disease monitoring and predicting clinical recurrence.
[Studies on the protein content in the aqueous humour of the living rabbits. 4. Effects of beta-stimulant and beta-blockade].

M. Takase

1971-01-20

Abstract:
Plasma alpha- and beta-mannosidase activities in caprine beta-mannosidosis.

K. Cavanagh,R. Dunstan,M. Jones

1982-06-01

American Journal of Veterinary Research

Abstract:Plasma alpha- and beta-mannosidase activities were measured in goats with beta-mannosidosis, a recently discovered, inherited deficiency of the glycohydrolase beta-D-mannosidase. Plasma beta-mannosidase activity in the affected animals was zero at 1 and 4 weeks after they were born. Enzyme values of age-matched, unaffected goats were between 66 and 222 nmol/hr/ml of plasma, alpha-Mannosidase activities were similar in both affected and unaffected animals. This investigation indicates that deficiency of plasma beta-mannosidases activity may be diagnostic of beta-mannosidosis.
Endogenous compounds labeled with radionuclides of short half-life-some perspectives.

B. Långström,F. Karimi,Y. Watanabe

DOI: https://doi.org/10.1002/jlcr.3033

2013-03-01

Abstract:In the article, the strategy and synthesis of some endogenous compounds labeled mainly with (11) C are presented. There are some examples illustrating how endogenous labeled compounds in connection with positron emission tomography have unique properties to describe various biological processes, and a few examples of the use of tracers labeled with (13) N and (15) O are also discussed. Labeled endogenous compounds may be an important asset to describe the conditions and the status of biological systems and might therefore be a key for the future search of individualized medicine.
Circulating Tumor DNA in Lymphoma

Swetha Kambhampati,Jasmine Zain

DOI: https://doi.org/10.1007/s11899-022-00677-1

Abstract:Purpose of review: Recent advances have been made in circulating tumor DNA (ctDNA), the method to minimally invasive detect lymphoma sensitively with tumor-derived DNA in the blood of patients with lymphomas. This article discusses these various methods of ctDNA detection and the clinical context in which they have been applied to for a variety of lymphoma subtypes. Recent findings: ctDNA has been applied to a variety of subtypes of lymphoma and has been used in the context of genotyping somatic mutations and classification of disease, monitoring of response during treatment, detecting minimal residual disease even with radiographic remission, and predicting relapse and long-term survival outcomes. There are a variety of techniques used to measure ctDNA including digital polymerase chain reaction and next-generation sequencing techniques including high-throughput variable-diversity-joining rearrangement sequencing, high-throughput sequencing of somatic mutations, and Cancer Personalized Profiling by deep sequencing. While the greatest data has been generated in diffuse large B cell lymphoma, there have been studies utilizing application of ctDNA in follicular lymphoma, mantle cell lymphoma, Hodgkin's lymphoma, peripheral T cell lymphoma, and primary CNS lymphoma among others. ctDNA is an emerging biomarker in lymphoma that can minimally invasively provide further genotypic information, diagnostic clarification, and treatment prognostication by detection of minimal residual disease even without radiographic evidence of disease. Future studies are needed to standardize the use of ctDNA and translate its use clinically for the management of lymphoma patients.
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research

Eliza M. Lauer,Jurik Mutter,Florian Scherer

DOI: https://doi.org/10.1038/s41375-022-01618-w

2022-06-15

Leukemia

Abstract:Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA) profiling has become a potential novel strategy for patient management in B-cell lymphoma. Emerging innovative therapeutic options and an unprecedented growth in our understanding of biological and molecular factors underlying lymphoma heterogeneity have fundamentally increased the need for precision-based tools facilitating personalized and accurate disease profiling and quantification. By capturing the entire mutational landscape of tumors, ctDNA assessment has some decisive advantages over conventional tissue biopsies, which usually target only one single tumor site. Due to its non- or minimal-invasive nature, serial and repeated ctDNA profiling provides a real-time picture of the genetic composition and facilitates quantification of tumor burden any time during the course of the disease. In this review, we present a comprehensive overview of technologies used for ctDNA detection and genotyping in B-cell lymphoma, focusing on pre-analytical and technical requirements, the advantages and limitations of various approaches, and highlight recent advances around improving sensitivity and suppressing technical errors. We broadly review potential applications of ctDNA in clinical practice and for translational research by describing how ctDNA might enhance lymphoma subtype classification, treatment response assessment, outcome prediction, and monitoring of measurable residual disease. We finally discuss how ctDNA could be implemented in prospective clinical trials as a novel surrogate endpoint and be utilized as a decision-making tool to guide lymphoma treatment in the future.

oncology,hematology
Circulating Tumor DNA Clearance During Treatment As a Predictive and Prognostic Biomarker for Diffuse Large B-Cell Lymphoma Patients Receiving First-Line Therapy

Yuqin Song,Miaomiao Li,Lan Mi,Chunyang Wang,Xiaojuan Wang,Jianhua Zhu,Fei Qi,Hui Yu,Yingying Ye,Dedao Wang,Jiaowu Cao,Dingyao Hu,Quanyu Yang,Dandan Zhao,Tonghui Ma,Jun Zhu

DOI: https://doi.org/10.1182/blood-2022-166170

IF: 20.3

2022-01-01

Blood

Abstract:Background: Circulating tumor DNA (ctDNA) dynamics has been proven to be a reliable outcome prediction biomarker in a plenty of solid tumors. However, its clinical utility in response assessment and prognosis prediction for diffuse large B-cell lymphoma (DLBCL) has not been well established. This study was aimed to explore the association between ctDNA dynamics and clinical benefits in a cohort of DLBCL patients. Methods: A total of 37 newly diagnosed DLBCL patients treated with first-line therapy were enrolled retrospectively in this study. Tumor biopsy tissues were collected at diagnosis (n = 17) and peripheral blood samples were obtained before treatment (n = 31) as well as after receiving the initial two treatment cycles (C2, n = 37). Tumor genomic DNA and cell-free DNA (cfDNA) were extracted from tumor tissues and plasma samples, respectively. Targeted next generation sequencing of 188 lymphoma associated genes (Onco-LymScan, Genetron Health) was performed in all of the tumor samples to identify disease-associated mutations. Genomic DNA extracted from the paired peripheral blood mononuclear cells were also sequenced and analyzed to filter out germline variants for each patient. Results: All of the 37 patients were identified at least one somatic mutation from their pretreatment tumor and/or plasma samples. We sought whether these basal mutations could be traced in the C2 plasma of each patient. Mutations that were only detected in C2 plasma were considered uninformative and were removed from analysis. Accordingly, 12 patients were identified at least one basal mutation at C2 and 25 patients showed a rapid clearance of these basal mutations. Based on the ctDNA clearance status at C2, patients were classified into two groups: the ctDNA clearance group (n = 25) and the ctDNA persistence group (n = 12). There were no significant difference in serval clinical factors such as age, B symptoms, LDH (Lactate Dehydrogenase) level, stage and IPI (International prognostic Index) between the two groups. In response to the first-line treatment, patients with a ctDNA clearance showed a significantly higher complete remission rate (62.5% vs. 23.1%, p = 0.038; Figure A) than the patients with a persistence of ctDNA. With a median follow-up visit period of 26.0 mouths, patients with a ctDNA clearance at C2 presented a favorable progression-free survival (median PFS, unreached vs. 5.45 months; HR 2.919; p = 0.0039; Figure B) and overall survival (median OS, 43.6 vs. 25.87 months; HR 2.758; p = 0.0393; Figure C) compared with those without a ctDNA clearance. These results indicated that patients achieving an early ctDNA clearance during treatment were more likely to achieve a superior later clinical benefit. Conclusions: Early ctDNA clearance during treatment could effectively serve as a predictive and prognostic biomarker for DLBCL patients receiving first-line therapy. Integrating ctDNA profiling into clinical disease management may help to identify patients at high-risk and contribute to individualized treatment. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
[Primary generalized amyloidosis accompanied by cholestatic icterus].

L. Bjerrum,I. Steiness

1980-07-21

Abstract:

[A family of lysophospholipid receptors].

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas

Choice of parenteral solutions for correcting metabolic acidosis.

Circulating Tumor DNA: Clinical Roles in Diffuse Large B Cell Lymphoma

Thallium Lung-to-Heart Quantification: Three Methods of Evaluation

Prevention of early familial maladjustment by parent-staff group meetings: influence of familial background.

A high frequency of structural chromosome abnormalities in a south central texas cytogenetics laboratory.

Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes

Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing

Validation of Circulating Tumor DNA As an Alternative to Tumor Tissue Biopsy in Genotyping across Multiple Lymphoma Subtypes

Clinical use of circulating tumor DNA analysis in patients with lymphoma

Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study

Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma

Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA

[Studies on the protein content in the aqueous humour of the living rabbits. 4. Effects of beta-stimulant and beta-blockade].

Plasma alpha- and beta-mannosidase activities in caprine beta-mannosidosis.

Endogenous compounds labeled with radionuclides of short half-life-some perspectives.

Circulating Tumor DNA in Lymphoma

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research

Circulating Tumor DNA Clearance During Treatment As a Predictive and Prognostic Biomarker for Diffuse Large B-Cell Lymphoma Patients Receiving First-Line Therapy

[Primary generalized amyloidosis accompanied by cholestatic icterus].